We did an open-label , randomised , @ factorial trial in men with locally advanced prostate cancer ( either T@a N@ M@ prostatic adenocarcinomas with prostate-specific antigen -LSB- PSA -RSB- @ g/L and a Gleason score of @ , or T@b-@ N@ M@ tumours regardless of PSA and Gleason score ) .